Home・Listă Acțiuni・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Închisă

SectorSănătate

5.89 -1.17

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

5.73

Maxim

Indicatori cheie
By Trading Economics
Venit	-187M -180M
Vânzări	78M 234M
P/E Medie Sector	8.634 57.366
EPS	0.6
Marjă de profit	-76.91
Angajați	900
EBITDA	-205M -156M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+67.5% upside

Dividende
By Acuity
Următoarele câștiguri	28 oct. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-112M 266M
Deschiderea anterioară	7.06
Închiderea anterioară	5.89

Sentimentul știrilor

By Acuity

20%

80%

46 / 340 Clasament în Healthcare

Emergent BioSolutions Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 aug. 2026, 20:07 UTC

News

Emergent BioSolutions Inc. is under investigation, following a $180.2 million net loss and reduced revenue guidance, contributing to a decline in shares today.

26 aug. 2026, 20:08 UTC

Emergent BioSolutions Inc shares are higher, reflecting strong upward momentum since Tuesday. The stock remains well above its 20-day moving average.

25 aug. 2026, 20:07 UTC

Emergent BioSolutions Inc shares are higher during Tuesday's session, continuing a strong advance since Monday's close amid easing Treasury yields and lower oil prices.

24 aug. 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a cumulative increase since Friday. The stock remains below its 20-day moving average.

21 aug. 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a steady upward trend since Thursday's close. No specific news was identified to explain the movement.

20 aug. 2026, 19:02 UTC

News

Emergent BioSolutions Inc faces scrutiny after a $191.3 million impairment charge and a reduced revenue outlook, contributing to a decline in shares.

19 aug. 2026, 19:52 UTC

Emergent BioSolutions Inc is trading higher during Wednesday's session, recovering from earlier lows and reflecting strength since Tuesday's close. No specific news was identified.

18 aug. 2026, 20:06 UTC

Emergent BioSolutions Inc shares are higher today, reflecting a broader market recovery. The stock remains below its 20-day moving average and prior month levels.

17 aug. 2026, 19:56 UTC

News

Emergent BioSolutions faces investigations over financial disclosures, including a $191.3 million impairment charge, contributing to lower shares amid declining investor confidence.

13 aug. 2026, 19:51 UTC

Macro Event

Emergent BioSolutions Inc shares are roughly flat as jobless claims rise to 209,000, exceeding expectations. The stock remains below its 20-day moving average.

12 aug. 2026, 19:26 UTC

Emergent BioSolutions Inc gains amid broader market optimism following inflation data. The stock reached a session high before slightly pulling back.

11 aug. 2026, 22:56 UTC

Emergent BioSolutions Inc shares are trading lower in after-market hours. No specific news was identified to explain the movement.

10 aug. 2026, 19:51 UTC

News

Emergent BioSolutions shares are trading lower as H.C. Wainwright reduced its price target to $10.00, citing concerns over performance and outlook amid competitive pressures.

7 aug. 2026, 23:26 UTC

Emergent BioSolutions Inc shares rose in after-market trading, amid positive market sentiment and notable gains in major tech stocks. No specific news was identified.

6 aug. 2026, 23:41 UTC

Emergent BioSolutions traded roughly flat after market hours, with no specific news identified. The stock has declined significantly over the past month.

5 aug. 2026, 22:51 UTC

News

Emergent BioSolutions shares are lower in after-market hours following a Q2 net loss of $180.2 million and reduced full-year sales guidance.

29 iul. 2026, 19:56 UTC

Emergent BioSolutions Inc shares are trading higher Wednesday, reflecting gains since Tuesday's close, despite earlier fluctuations and broader market pressures.

27 iul. 2026, 18:46 UTC

Emergent BioSolutions Inc shares are higher amid a broader market trend, despite pulling back from earlier session highs. Crude oil prices have significantly declined.

23 iul. 2026, 19:36 UTC

Emergent BioSolutions Inc shares are lower, reflecting broader market trends amid negative earnings from major technology companies like Tesla and Alphabet.

Comparație

Modificare preț

Emergent BioSolutions Inc Așteptări

Obiectiv de preț

By TipRanks

67.5% sus

Prognoză pe 12 luni

Medie 10 USD 67.5%

Maxim 10 USD

Minim 10 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEmergent BioSolutions Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Emergent BioSolutions Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

46 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.